| Literature DB >> 27246657 |
Chao Zhang1, Yao Yao2, Juan-Li Zhu2, Si-Nong Zhang1, Shan-Shan Zhang1, Hua Wei1, Wen-Li Hui1,2, Ya-Li Cui1,2.
Abstract
Single-nucleotide polymorphisms (SNPs) represent the most widespread type of genetic variation (approximately 90%) in the human genome, and the demand to overcome such variation has received more attention now than ever before. The capacity to rapidly assess SNPs that correlate with disease predisposition, drug efficacy and drug toxicity is a key step for the development of personalized medicine. In this work, a rapid one-step SNP detection method, real-time loop-mediated isothermal amplification (RT-LAMP), was first applied for CYP2C19 polymorphisms testing. The optimized method was established with specifically designed primers for target amplification by real-time detection in approximately 30 min under isothermal conditions. RT-LAMP amplified few copies of template to produce significant amounts of product and quantitatively detected human DNA with compatible specificity and sensitivity. The success in the establishment of this RT-LAMP protocol for CYP2C19 polymorphism testing is significant for the extension of this technique for the detection of other SNPs, which will further facilitate the development of personalized medicine.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27246657 PMCID: PMC4887897 DOI: 10.1038/srep26533
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Primer sequences used for sequencing, RT-LAMP and conventional PCR reactions.
| Allele | Application | Primer | Sequence |
|---|---|---|---|
| Sequencing | *2-seq-F | 5′-CAACCAGAGCTTGGCATATTG-3′ | |
| *2-seq-R | 5′-CAATAAAGTCCCGAGGGTTGT-3′ | ||
| RT-LAMP | *2-FIP-A | 5′-TGGGAAATAATCAATG-CTATACCTTTATTAAATGC-3′ | |
| *2-FIP-G | 5′-CGGGAAATAATCAATG-CTATACCTTTATTAAATGCT-3′ | ||
| *2-BIP-A | 5′-AGGAACCCATAACAAATTACTT-GTTCTTTTACTTTCTCC-3′ | ||
| *2-BIP-G | 5′-GGGAACCCATAACAAATTACTT-GTTCTTTTACTTTCTCC-3′ | ||
| *2-F3 | 5′-CAGAGCTTGGCATATTGTAT-3′ | ||
| *2-B3 | 5′-TAAAGTCCCGAGGGTTGTTG-3′ | ||
| Conventional PCR | *2-F | 5′ ACAACCAGAGCTTGGCATATTGT-3′ | |
| *2-R-A | 5′- GGTTTTTAAGTAATTTGTTATGGGTTGCT-3′ | ||
| *2-R-G | 5′- TTTTTAAGTAATTTGTTATGGGTTGCC-3′ | ||
| Sequencing | *3-seq-F | 5′-AGGCTGTAATTGTTAATTCGAGA-3′ | |
| *3-seq-R | 5′-TGTACTTCAGGGCTTGGTCA-3′ | ||
| RT-LAMP | *3-FIP-A | 5′-TCAGGGGGTGCTTACAATCCTG-AGATCAGCAATTTCTTAACTTGA-3′ | |
| *3-FIP-G | 5′-CCAGGGGGTGCTTACAATCCTG-AGATCAGCAATTTCTTAACTTGA-3′ | ||
| *3-BIP-A | 5′-AATCCAGGTAAGGCCAAGTTT-TGTACTTCAGGGCTTGGTC-3′ | ||
| *3-BIP-G | 5′-GATCCAGGTAAGGCCAAGTTT-TGTACTTCAGGGCTTGGTC-3′ | ||
| *3-F3 | 5′-ATTTTCCAGAAACGTTTCGA-3′ | ||
| *3-B3 | 5′-TGTCTAGGCAAGACTGTAGT-3′ | ||
| Conventional PCR | *3-F | 5′- TGTGCTCCCTGCAATGTGAT-3′ | |
| *3-R-A | 5′- AAAAAACTTGGCCTTACCTGGAAT-3′ | ||
| *3-R-G | 5′- AAAAACTTGGCCTTACCTGGAAC-3′ |
Figure 1Schematic of primers and the RT-LAMP-based SNP detection process.
Figure 2RT-LAM-based detection of CYP2C19*2 and CYP2C19*3.
(A–C): using CYP2C19*2 G681G, CYP2C19*2 A681A and mixed plasmids as templates, respectively; (D–F): using CYP2C1*3 G636G, CYP2C19*3 A636A and mixed plasmids as templates, respectively. The following genotypes were identified: CYP2C19*2 G681G, CYP2C19*2 A681A, CYP2C19*2 G681A, CYP2C19*3 G636G, CYP2C19*3 A636A, and CYP2C19*3 G636A.
Figure 3Sensitivity of the RT-LAMP assay using CYP2C19 G681G plasmid.
(A) Sensitivity of the RT-LAMP assay as monitored using the Genie II system. (B) The standard curve was generated from a dilution series of plasmid by plotting the Tpeek versus the plasmid copy number.
Gene test results and frequency of 200 clinical samples of CYP2C19 alleles (type-specific concordance among RT-LAMP, conventional PCR and direct sequencing).
| RT-LAMP | Conventional PCR (n = 100) | Total | Sequencing (n = 100) | Total | Agreement (%) | Frequency (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *1/*1 | *2/*2 | *3/*3 | *1/*2 | *1/*3 | *2/*3 | *1/*1 | *2/*2 | *3/*3 | *1/*2 | *1/*3 | *2/*3 | |||||
| *1/*1 | 51 | 0 | 0 | 0 | 0 | 0 | 51 | 51 | 0 | 0 | 0 | 0 | 0 | 51 | 100% | 51% (F1) |
| *2/*2 | 0 | 6 | 0 | 0 | 0 | 0 | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 6 | 100% | 6% (F2) |
| *3/*3 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 100% | 2% (F3) |
| *1/*2 | 0 | 0 | 0 | 35 | 0 | 0 | 35 | 0 | 0 | 0 | 35 | 0 | 0 | 35 | 100% | 35% (F4) |
| *1/*3 | 0 | 0 | 0 | 0 | 4 | 0 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 4 | 100% | 4% (F5) |
| *2/*3 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 100% | 2% (F6) |
| Total | 51 | 6 | 2 | 35 | 4 | 2 | 100 | 51 | 6 | 2 | 35 | 4 | 2 | 100 | 100% | 100% |
*1/*1: CYP2C19*2 G681G type, CYP2C19*3 G636G type; *2/*2: CYP2C19*2 A681A type, CYP2C19*3 G636G type; *3/*3: CYP2C19*2 G681G type, CYP2C19*3 A636A type, *1/*2: CYP2C19*2 G681A type, CYP2C19*3 G636G type; *1/*3: CYP2C19*2 G681G type, CYP2C19*3 G636A type; *2/*3: CYP2C19*2 G681A type, CYP2C19*3 G636A type.